{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"T-cell malignancies expressing CD5 antigen","name":"MAGENTA","nct_id":"NCT03081910","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=magenta-nct03081910. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MAGENTA","arms":[{"description":"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.\n\nOnce dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data.","label":"Autologous CD5.CAR/28zeta CAR T cells (Group A) - NOW CLOSED","type":"EXPERIMENTAL"},{"description":"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.\n\nOnce dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data.","label":"Allogeneic CD5.CAR/28zeta CAR T cells (Group B)","type":"EXPERIMENTAL"}],"collaborators":["Center for Cell and Gene Therapy, Baylor College of Medicine","The Methodist Hospital Research Institute","National Cancer Institute (NCI)"],"completion_date":{"date":"2040-09-01","type":"ESTIMATED"},"conditions":["T-cell Acute Lymphoblastic Lymphoma","T-non-Hodgkin Lymphoma","T-cell Acute Lymphoblastic Leukemia"],"enrollment":{"count":104,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Autologous CD5.CAR/28zeta CAR T cells","otherNames":[],"type":"GENETIC"},{"name":"Allogeneic CD5.CAR/28zeta CAR T cells","otherNames":[],"type":"GENETIC"}],"last_update":"2026-11-04","lead_sponsor":"Baylor College of Medicine","official_title":"Phase 1 Therapy With Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2028-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose limiting toxicity (DLT) rate","timeFrame":"6 weeks post-infusion"}],"references":[{"citation":"Dai Z, Mu W, Zhao Y, Jia X, Liu J, Wei Q, Tan T, Zhou J. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains. Mol Ther. 2021 Sep 1;29(9):2707-2722. doi: 10.1016/j.ymthe.2021.07.001. Epub 2021 Jul 16.","pmid":"34274536","type":"DERIVED"}],"start_date":{"date":"2017-11-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen","url":"https://clinicaltrials.gov/study/NCT03081910"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/magenta-nct03081910"}